Thus, PARP-1 may be an important target for BRCA-deficient breast cancer chemotherapy [8-11], as emphasized also by the clinical activity of the PARP inhibitor (PARPi) olaparib in patients with BRCA-mutated breast cancer [3]. Here, PARP1 is linked to breast cancer.